Alembic Pharmaceuticals

Market Cap

16,006.14 Cr

EPS

31.33

PE Ratio

26.85

Dividend Yield

1.35 %

Industry

Healthcare

52 Week High

1,303.90

52 Week low

788.15

PB Ratio

3.27

Debt to Equity

0.13

Sector

Pharmaceuticals

Investment Returns

In Long Term

In Short Term

1 Year

0.00%

2 Years

0.00%

3 Years

0.00%

4 Years

0.00%

5 Years

0.00%

Analyst Rating

- By Refinitiv from10 analysts

Analysts have suggested that investors can hold this stock

Buy40.00 %

40.00 %

Hold50.00 %

50.00 %

Sell10.00 %

10.00 %

Company News

View All News

Alembic Pharmaceuticals Receives EIR for Solid Oral Formulation Facility3 days ago

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) for its Solid Oral Formulation Facility (F-4) located in Jarod. The EIR was classified as Voluntary Action Indicated (VAI), suggesting minor issues that the company can address voluntarily.

Alembic Pharmaceuticals: FDA Classifies Vadodara Unit as 'Voluntary Action Indicated'6 days ago

Alembic Pharmaceuticals' solid oral formulation facility in Vadodara receives Establishment Inspection Report from FDA with 'Voluntary Action Indicated' classification following November 2024 inspection. The facility can continue selling approved drugs and receive new filing approvals.

Alembic Pharmaceuticals Receives EIR for Solid Oral Formulation Facility6 days ago

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) for its solid oral formulation facility (F-4) located in Jarod. The EIR classification is 'Voluntary Action Indicated', suggesting minor issues that the company can address voluntarily.

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,669.30	4,00,520.99	34.13	49,887.20	12.06	9,648	13.77	37.74
Divis Laboratories	5,978.30	1,58,705.08	76.14	8,184.00	0.89	1,600	64.53	51.57
Cipla	1,479.70	1,19,502.65	23.70	26,520.70	14.17	4,155	47.38	51.15
Torrent Pharmaceuticals	3,095.95	1,04,781.02	56.64	10,785.70	11.59	1,656	13.54	45.77
Dr Reddys Laboratories	1,170.95	97,705.34	18.09	28,905.40	12.36	5,578	1.69	30.83
Mankind Pharma	2,348.45	96,889.27	47.77	10,615.60	19.57	1,942	-16.38	39.42
Zydus Life Science	899.65	90,525.84	19.78	19,831.50	13.82	3,831	29.92	36.77
Lupin	1,977.50	90,213.07	31.46	20,141.50	19.94	1,936	38.82	38.83
Aurobindo Pharma	1,121.25	65,122.38	18.72	29,559.20	17.55	3,169	-10.04	42.81
Abbott	29,429.65	62,535.95	47.37	6,097.20	10.80	1,201	16.01	61.56

Growth Rate

Revenue Growth

10.64 %

Net Income Growth

80.06 %

Cash Flow Change

10.95 %

ROE

63.22 %

ROCE

54.94 %

EBITDA Margin (Avg.)

22.28 %

Quarterly Financial Results

Quarterly Financials	Mar 2015	Jun 2015	Sept 2015	Dec 2015	Mar 2016	Jun 2016	Sept 2016	Dec 2016	Mar 2017	Jun 2017	Sept 2017	Dec 2017	Mar 2018	Jun 2018	Sept 2018	Dec 2018	Mar 2019	Jun 2019	Sept 2019	Dec 2019	Mar 2020	Jun 2020	Sept 2020	Dec 2020	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Revenue	504	582	1,003	918	630	737	880	777	742	648	797	840	854	863	1,129	1,022	930	952	1,241	1,210	1,243	1,342	1,460	1,317	1,306	1,328	1,313	1,291	1,426	1,263	1,475	1,510	1,407	1,498	1,605	1,634	1,521	1,564	1,678	1,703
Expenses	405	478	629	532	484	580	702	632	606	547	610	653	680	712	825	776	749	757	895	884	926	934	1,014	949	960	1,090	1,054	1,030	1,268	1,255	1,244	1,274	1,203	1,288	1,387	1,364	1,257	1,325	1,409	1,433
EBITDA	99	103	375	386	146	158	178	146	136	102	187	188	174	151	305	246	181	195	346	326	318	408	447	368	346	238	259	261	158	9	231	236	205	210	218	269	263	239	270	270
Operating Profit %	19 %	18 %	37 %	42 %	23 %	21 %	20 %	19 %	18 %	16 %	23 %	22 %	20 %	18 %	27 %	24 %	19 %	20 %	28 %	27 %	23 %	30 %	30 %	28 %	25 %	18 %	18 %	19 %	10 %	1 %	16 %	16 %	14 %	13 %	13 %	16 %	17 %	15 %	15 %	15 %
Depreciation	11	13	13	22	24	19	21	21	22	22	26	26	32	28	29	29	30	35	36	42	44	42	44	47	51	53	55	56	123	67	68	67	74	66	68	69	70	69	71	70
Interest	0	1	1	1	2	1	1	1	2	1	0	1	1	2	6	6	5	5	7	7	8	7	5	2	3	2	5	4	7	9	12	15	14	14	16	15	11	13	19	22
Profit Before Tax	89	91	362	364	120	137	157	124	112	79	161	161	141	122	270	211	146	155	303	276	266	360	398	318	292	183	200	201	29	-67	151	155	116	130	135	185	183	157	180	178
Tax	18	19	73	95	29	33	37	37	19	12	39	30	47	32	70	42	23	36	52	49	62	66	73	33	49	24	36	29	7	-2	18	33	-36	9	-2	4	5	23	27	40
Net Profit	70	72	289	269	91	104	120	87	93	67	122	131	94	90	200	169	124	120	250	227	204	293	325	286	243	158	164	172	22	-66	133	122	153	121	137	180	178	135	153	138
EPS in ₹	3.73	3.72	15.30	14.26	4.82	5.50	6.36	4.59	4.94	3.54	6.45	6.93	4.98	4.80	10.61	9.01	6.58	6.56	13.06	12.42	11.93	15.99	17.24	14.88	12.75	8.37	8.34	8.74	1.11	-3.35	6.78	6.20	7.76	6.14	6.95	9.23	8.48	6.84	7.79	7.01

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,641	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446
Fixed Assets	547	708	799	993	1,159	1,552	1,788	1,798	2,398	2,547
Current Assets	891	1,511	1,373	1,825	1,958	2,463	2,652	2,861	2,910	3,079
Capital Work in Progress	83	93	396	1,010	1,551	1,846	2,183	2,304	601	524
Investments	0	53	50	42	49	18	236	118	96	93
Other Assets	1,011	1,575	1,444	1,896	2,019	2,573	2,502	2,902	3,087	3,282
Total Liabilities	1,641	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446
Current Liabilities	684	747	693	1,144	1,490	1,752	1,281	1,717	1,637	1,455
Non Current Liabilities	72	84	94	576	570	1,047	361	168	175	172
Total Equity	885	1,597	1,902	2,220	2,718	3,190	5,067	5,238	4,371	4,818
Reserve & Surplus	847	1,560	1,865	2,182	2,681	3,182	5,028	5,198	4,331	4,779
Share Capital	38	38	38	38	38	38	39	39	39	39

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Cash Flow	3	417	-286	-69	115	-127	26	-37	14	45
Investing Activities	-256	-307	-486	-884	-756	-731	-840	-372	-448	-321
Operating Activities	172	948	329	312	812	449	1,463	552	724	803
Financing Activities	87	-224	-129	503	59	155	-597	-217	-262	-438

Show % Change

Above figures are in Rs. Crores

Share Holding

% Holding	Mar 2021	Jun 2021	Sept 2021	Dec 2021	Mar 2022	Jun 2022	Sept 2022	Dec 2022	Mar 2023	Jun 2023	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024
Promoter	69.48 %	69.48 %	69.48 %	69.48 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %	69.61 %
FIIs	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	4.52 %	4.46 %	4.32 %	3.94 %	4.17 %
DIIs	10.92 %	11.17 %	11.36 %	11.56 %	11.69 %	12.06 %	12.43 %	12.76 %	13.31 %	13.40 %	13.93 %	14.50 %	15.38 %	15.47 %	16.05 %	16.06 %
Government	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Public / Retail	10.99 %	10.78 %	11.43 %	9.57 %	9.22 %	8.91 %	9.12 %	9.21 %	9.08 %	8.98 %	8.24 %	8.00 %	7.41 %	7.48 %	7.36 %	7.26 %
Others	8.61 %	8.57 %	7.73 %	9.39 %	9.47 %	9.41 %	8.84 %	8.42 %	8.00 %	8.01 %	8.22 %	3.37 %	3.14 %	3.13 %	3.04 %	2.90 %
No of Share Holders	0	0	99,809	1,01,686	1,23,059	1,10,038	1,06,437	1,01,457	1,03,811	97,607	89,552	85,212	76,567	74,829	91,429	93,944